MADISON, Wis.--(BUSINESS WIRE)--HealthMyne, an imaging informatics company, today announced the addition of Robert Gillies, PhD to its Advisory Board. Dr. Gillies is currently the Chair of the Department of Cancer Imaging and Metabolism at the H. Lee Moffitt Cancer Center and Research Institute.
“Our collaborations with Dr. Gillies have been ongoing for over a year and we are excited to formalize this very productive relationship with a global thought leader in the emerging field of radiomics, said Roger Chylla, CTO of HealthMyne. "We want our clinical imaging analytics platform to not only enhance the standard workflow of cancer care providers but also accelerate translational research aimed at defining impactful diagnostic and prognostic cancer models.”
During his career, Dr. Gillies has published over 240 peer-reviewed articles in the use of imaging and spectroscopy to interrogate tumor physiology. He is also currently the PI (principle investigator) or co-PI on eight NCI grants or sub-contracts focused on cancer imaging.
“HealthMyne has the opportunity to make a significant impact in the field of imaging analysis, said Dr. Gillies. “We have only really begun to tap into the extensive data contained in clinical images, and HealthMyne is an important enabler of that data mining – in both a research and clinical setting. In the end, we are all focused on improving cancer diagnosis and treatment.”
HealthMyne will be exhibiting (North Building, Hall B, Booth 8310) at the Annual Meeting of the Radiological Society of North America in Chicago from November 29 to December 4, 2015.
HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports. HealthMyne software will combine imaging and electronic health record data to provide stakeholders with integrated patient progression timelines as well as analytics for comparing individual patients to specific populations. Academic and industrial researchers can use HealthMyne analytic tools to explore quantitative imaging biomarkers, including radiomic signature development, as well as supporting improved clinical trials of innovative therapies.